Compounder Definition In House Bill May Use Blended Metrics
This article was originally published in The Pink Sheet Daily
FDA and stakeholders reiterate that volume cannot be the sole measure of whether a compounder should be regulated like a drug manufacturer; Rep. Griffith pitches potentially using it and other indicators to draw the line.
You may also be interested in...
HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.
Biden administration sets May 11 as end date for public health emergency. CDER has said it will work with sponsors to help them gain approval of COVID therapeutics cleared under emergency use authorizations, but agency will likely not issue a formal transition framework.
OTAT Director Bryan, who has worked at the FDA for more than 20 years, will depart by the end of March as the agency’s cell and gene therapy operations are poised for a major overhaul and a large number of new hires.